Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01064726 | A Study To Explore The Effect On Inflammatory Markers After Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis And The Effect Of A Single Dose Of Ibuprofen Or Fluticasone Propionate On The Allergen Response. | PHASE1 | COMPLETED | 18 | — | — | Oct 1, 2009 | Apr 1, 2010 | Jun 2, 2010 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Ibuprofen | EXPERIMENTAL | - |
| Fluticasone propionate | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Ibuprofen | DRUG | 800 mg oral |
| Fluticasone propionate | DRUG | 200 mcg intra-nasal |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Male or female subjects with seasonal allergic rhinitis (out of season). * Sensitive to ragweed skin prick test and screening nasal allergen challenge. Exclusion Criteria: * Subjects with significant concomitant diseases. * Subjects with symptoms of allergic rhinitis in 2 we...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150, Standard therapy for INCS |
| Polyrizon Ltd. | PLRZ | 1 | NA | Undisclosed |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | — | Undisclosed |